Atrial secondary tricuspid regurgitation: pathophysiology, definition, diagnosis, and treatment

European Society of Cardiology European Society of Cardiology Journals

academic.oup.com/eurheartj/arti…

What a great experience learning from Stéphane Rinfret, MD SM directly “chez nous, chez lui”. Thanks for all your time, tips & tricks and the #CTO potpourri lectures! Hasta la próxima! #UseAFoley

Esperamos que este artículo ayude a todos los que quieren hacer BUENA investigación. Gracias Almudena Castro Conde Ignacio Ferreira Gonzalez !
Ética en la investigación clínica: qué debe saber antes de iniciar un estudio #REC revespcardiol.org//es-etica-inve…

Estos mensajes resurgen con fuerza cada cierto tiempo. Ya hablé de ello en varias ocasiones, pero parece que hay que insistir. Sigue>>

What do you do when still significant bleeding after pre-closure for TAVR??

Our paper in JSCAI on collagen-mediate closure (MANTA/Angioseal) vs suture-mediate closure might give you the right answer ;)
#TAVR
#cardiotwitter
MyJSCAI
Teleflex Interventional Cardiology

jscai.org/article/S2772-…

John Mandrola, MD In about 50% of cases, a single imaging modality was employed. The criteria of a lumen area smaller than 4.0 mm² combined with a plaque burden exceeding 70% were the top two characteristics and can be easily assessed in clinical practice.

This study described the characteristics and outcomes of TAVI patients with significant concomitant MR of different aetiologies. It demonstrated that increased MR severity at baseline contributes to worse outcomes following TAVI. EIJBestOf ow.ly/rHxu50Rbqvt

Over the last three days, we’ve seen almost all pharmacological strategies presented at #ACC24 fail, including beta blockers, which seemed like the only certainty. On the contrary, if we are to believe in the results we've seen, we should start using more microaxial flow pump

Incidencia, predictores e impacto pronóstico de una clase funcional disminuida inmediatamente después de un implante percutáneo de válvula aórtica #REC #AheadOfPrint Jorge Nuche Julien Ternacle Marisa Avvedimento Gabriela Veiga Fernández Victoria Vilalta Ander Regueiro Lluis Asmarats Pablo Vidal Calés

PREVENT trial: La placa vulnerable es the 🗝️
#LaSECtelleva #ACC24

Presented today at #ACC24 :

A randomized trial that enrolled patients with severe aortic stenosis at low or intermediate surgical risk showed that TAVI was noninferior to SAVR at 1 year. Read the full DEDICATE-DZHK6 trial results: nej.md/3TLx8MT

Thrilled to be co-author of this terrific document focused on management of electrical storm presented today at #EHRA2024 , which also highlights the role of MCS in this setting. academic.oup.com/europace/artic…
Leiden Electrophysiology Hartcentrum Leiden EHRAPresident European Society of Cardiology EuroELSO EAPCIPresident

This paradigm also applies to students, residents and fellows!
© Roberto Ferraro - robertoferraro.art

🆕Por fin!
📌El impella CP reduce la ☠️ en pacientes con IAM 🫀 Killip IV donde el BCIAO y el ECMO no lo habían conseguido #ACC24
Veamos a ver qué dice este estudio rompedor que dará que hablar y cambiará (para algunos espero 😏) práctica clínica👇 🧵

Presented at #ACC24 :

Hospitalized patients with acute myocardial infarction & preserved EF were assigned to receive open-label long-term beta-blocker therapy or not. Beta-blockers did not lead to a lower risk of death or MI. Full REDUCE-AMI trial results: nej.md/4akVhRx

¿Y por qué esta ocasión los investigadores han acertado con su hipótesis?

En mi opinión, una de las claves está en evitar las PCR prolongadas cuya etiología del shock no tiene que ver únicamente con la función cardiaca y cuya causa de muerte más frecuente es el daño cerebral

SMART trial presented with no surprises. nejm.org/doi/full/10.10… NEJM American College of Cardiology #ACC2024

One of the most interesting slides I've seen from RELIEVE-HF #ACC24

Strikingly different results in subgroups by EF! Incredibly divergent responses for differing physiology

RELIEVE-HF
shunt intraatrial: neutro pero
☑️ en ICFEr
❌ en ICFEp
Mucho para discutir y
#LaSECtelleva al resumen del estudio en el IN, su discusión en el POST.

Y esta tarde a 19 h🇪🇸:twitter spaces, primeras impresiones y reflexiones del Julio IP del trial y Manuel Anguita

In EMPACT-MI, a randomized trial involving 6522 patients post-acute myocardial infarction, empagliflozin did not significantly reduce the combined outcome of heart failure hospitalization or death compared to placebo over a period of 17.9 months.

Once again, a drug that